PTCT Q2 2023 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$214M+29.2% YoY

Gross Profit

$201M94.0% margin

Operating Income

-$210M-98.0% margin

Net Income

-$199M-93.0% margin

EPS (Diluted)

$-2.66

QoQ Revenue Growth

-3.0%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$33M

Stock-Based Comp.

$59M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$1.9B

Stockholders' Equity

-$579M

Cash & Equivalents

$208M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$214M	$166M	+29.2%
Gross Profit	$201M	$156M	+29.0%
Operating Income	-$210M	-$92M	-126.9%
Net Income	-$199M	-$152M	-30.8%

Revenue Segments

Manufacturing

$2M100%

Geographic Segments

Non-US

$97M59%

United States

$66M41%